netFormulary The Pennine Acute Hospitals NHS
NHS Trust Formulary  
 Formulary Chapter 2: Cardiovascular system - Full Chapter
02.01.01  Expand sub section  Cardiac glycosides
View adult BNF View SPC online View childrens BNF  Track Changes
  • Tablets
  • Liquid
  • Injection

  • When switching from oral to intravenous digoxin, the intravenous dose should be approximately 70% of the oral dose.

    GMMMG does not recommend digoxin as first-line for rate control of atrial fibrillation in ambulant patients.

    For plasma concentration monitoring, blood should be taken at least 6 hours after a dose.

    Link  PAHT Adult Loading Doses Policy
    02.01.01  Expand sub section  Digoxin-specific antibody
    Digoxin specific antibody fragments (Digifab)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Formulary See link for SPC 
    Link  DigiFab UKPAR (includes SPC)
     Non Formulary Items

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    note Notes
    Section Title Section Title (top level)
    Section Title Section Title (sub level)
    First Choice Item First Choice item
    Non Formulary Item Non Formulary section
    Restricted Drug
    Restricted Drug
    Unlicensed Drug
    Track Changes
    Display tracking information
    click to search
    Link to adult BNF
    click to search
    Link to children's BNF
    click to search
    Link to SPCs
    Scottish Medicines Consortium
    Cytotoxic Drug
    Cytotoxic Drug
    Controlled Drug
    High Cost Medicine
    High Cost Medicine
    Cancer Drugs Fund
    Cancer Drugs Fund
    NHS England

    Traffic Light Status Information

    Status Description


    Drugs designated amber are suitable for shared care arrangements under a shared care protocol. Prescribing may be transferred from secondary to primary care once the patient is stabilised and agreed shared care arrangements have been established. Alternatively primary care may initiate under the supervision of secondary care if this option is given in the shared care document. It is recommended that shared care arrangements should be drawn up following local discussion and agreement by prescribing parties.   


    These products have been reviewed by the GM Joint Formulary Group and have been deemed not suitable for prescribing for adults in primary or secondary care within Greater Manchester. These decisions have been made on the basis of safety, efficacy and cost-effectiveness of the products.  


    Not used   

    Green 1

    Drugs designated green1 are suitable for initiation and ongoing prescribing within primary care.   

    Green 2

    Drugs designated green2 can be initiated by primary care following written or verbal advice from a specialist and then be subsequently safely prescribed in primary care with little or no monitoring required.  

    Green 3

    Drugs designated green3 are suitable for on-going prescribing within primary care after specialist initiation and an initial review (unless specified) in secondary care. Little or no monitoring is required.  


    Not suitable for routine prescribing but may be suitable for a defined patient population. Whilst prescribers should think very carefully before prescribing or recommending any of the products on the grey list, there may be exceptional instances when the use of one of these products is necessary for a particular patient.   


    Drugs designated red are considered to be specialist medicines and prescribing responsibility for these medicines should normally remain with the consultant or specialist clinician. These drugs should not be initiated or prescribed in primary care. It is recommended that the supply of these specialist medicines should be organised via the hospital pharmacy, this may include arranging for supply via a home care company.